Frequencies for first 10,000 rows of lit_ref variable in demo2015q4 dataset : Literature Reference | Freq. Percent Cum. ----------------------------------------+----------------------------------- | 9,597 95.97 95.97 , BROWN R, ENEJOSA J, BERENGUER M, KW.. | 1 0.01 95.98 , CHIAPPELLA A, GHIONE P, MATTEUCCI .. | 1 0.01 95.99 , CHOI J, KIM I, LOUIE S, CISNEROS K,.. | 1 0.01 96.00 , CLARINGBOLD P AND TURNER J HEMATOLO.. | 2 0.02 96.02 , COLOMBO M, FERNANDEZ I, ABDURAKHM.. | 1 0.01 96.03 , DUMORTIER J, BOTTA-FRIDLUND D, LATO.. | 1 0.01 96.04 , EFFECT OF INTRAVENOUS RECOMBINANT T.. | 1 0.01 96.05 , FERRO A, LOMBARDI G, FARINA P, AND .. | 1 0.01 96.06 , FOPPOLI M, CITTERIO G,CABRAS M, PAT.. | 1 0.01 96.07 , GANE E, AGARWAL K, COHEN D, XIE W, .. | 1 0.01 96.08 , HE A, MONTOTO, S, KASSAM, S, MEE, M.. | 1 0.01 96.09 , HOCHART A, GAILLARD V, BARONCINI M,.. | 1 0.01 96.10 , HUANG C-L, ITOTANI R AND FUKUI M. E.. | 1 0.01 96.11 , ITO T, KANAI T, MURAYAMA K, KOYAMA .. | 1 0.01 96.12 , JANUS N, BEUZEBOC P, DANIEL C, RAY-.. | 1 0.01 96.13 , JONES S, HART L, PANT S, MOYHUDDIN .. | 1 0.01 96.14 , JUNG S, JOHNSON J, PITCHER B, BARTL.. | 1 0.01 96.15 , KALACHAND R, KING S, O^FARRELL N, P.. | 1 0.01 96.16 , KARTHAUS M, HECHT J, FASOLA G, CANO.. | 1 0.01 96.17 , KRAMKIMEL N, FRANCK N, LAURENT-RO.. | 1 0.01 96.18 , LAURENTI L, AUTORE F, INNOCENTI I,.. | 1 0.01 96.19 , MARKIEWICZ-KIJEWSKA M, KALICINSKI P.. | 1 0.01 96.20 , MARTIN D, PHILIP M, SHUSTOV A, SHUS.. | 1 0.01 96.21 , MARTIN P, SHAH B, SCHUSTER S, SMITH.. | 1 0.01 96.22 , MCCARVILLE M, WU J, DAVIDOFF A, SAN.. | 1 0.01 96.23 , MORTIMER J, YUAN Y, JUNG J, KRUPER .. | 2 0.02 96.25 , MUKHERJEE S, BRIDGEWATER J, FALK S,.. | 1 0.01 96.26 , MUKHERJEE S, BRIDGEWATER J, FALK S,.. | 1 0.01 96.27 , POLIZZOTTO M, GONCALVES P, ALEMAN K.. | 1 0.01 96.28 , PUJADE-LAURAINE E AND ALEXANDRE J. .. | 1 0.01 96.29 , SAMOILOVA O, OSMANOV E, EOM H-S, TO.. | 1 0.01 96.30 , SANDOVAL SUS J, GOODMAN D, ARTEAGA .. | 1 0.01 96.31 , SCHNEEWEISS A, LOIBL S, UNTCH M, PA.. | 1 0.01 96.32 , SHAH K, BUSAIDY N, WAGUESPACK S, HA.. | 1 0.01 96.33 , SHINTOU OSAMU, MIZUYAMA YOUKO, MATS.. | 1 0.01 96.34 , TADAHIKO J, HIROSHI M AND SUGIYAMA .. | 1 0.01 96.35 , TAKANO M, KOUTA H, KUDOH K, KITA T,.. | 1 0.01 96.36 , TAYAMA D, COHEN, G, LINDLEY R, WARD.. | 1 0.01 96.37 , TESAR B, YU L, WERNER L, TAKEBE N, .. | 1 0.01 96.38 , WANG X D, CHAN P, AHMAD A, FREEMAN .. | 1 0.01 96.39 , WANG X D, CHAN P, AHMAD A, FREEMAN .. | 1 0.01 96.40 , WAX S, LI Y AND TAK P. SAFETY AND E.. | 1 0.01 96.41 , YANG Y, ZHANG P, ZHANG J, ZHOU J, T.. | 1 0.01 96.42 , YASUNO M, ISHIGURO M, KAMEOKA S, SH.. | 1 0.01 96.43 , YOTHERS G, O^CONNELL M, BEART R, WO.. | 1 0.01 96.44 , YUAN Y, JUNG J, KRUPER L, STEWART D.. | 1 0.01 96.45 , YUAN Y, JUNG J, KRUPER L, STEWART D.. | 1 0.01 96.46 , YUAN Y, JUNG J, KRUPER L, STEWART D.. | 2 0.02 96.48 . CHARACTERISTICS AND MANAGEMENT OF R.. | 1 0.01 96.49 . THE EFFICACY AND SAFETY OF PEMETREX.. | 1 0.01 96.50 . UNKNOWN. RHEUMATOLOGY CONFERENCE 20.. | 2 0.02 96.52 A ANTEZANA, S SIGAL, J HERBERT, I KIS.. | 2 0.02 96.54 A FONCUBIERTA, D GUTIERREZ, F MEDINA,.. | 1 0.01 96.55 ACCORINTI M, GILARDI M, DE GERONIMO D.. | 1 0.01 96.56 AGGARWAL A, KAUL V, KAUR G, BANAS E, .. | 1 0.01 96.57 AK BLYSTAD. MULTIMODAL TREATMENT WITH.. | 1 0.01 96.58 AKASHI M,ANDO T,HAMASHIMA T,YOSHITA H.. | 1 0.01 96.59 AKIYAMA H, HAGA Y, SASAKI N, YANAGISA.. | 1 0.01 96.60 ALBUQUERQUE A, LOPES S, OSORLO F, ROD.. | 1 0.01 96.61 ALECK KA, BARTLEY DL. MULTIPLE MALFOR.. | 1 0.01 96.62 AMER H, CHEUNGPASITPORN W, CHEBIB F, .. | 1 0.01 96.63 ANDRE K, MARC L . ELDERLY PATIENT RE.. | 1 0.01 96.64 ANTEZANA A. SIGAL S. HERBERT J. KISTE.. | 1 0.01 96.65 ARDANZA-TREVIJANO, C. DELIRIUM UNDER .. | 1 0.01 96.66 ARITA K. A CASE OF REFRACTORY CHRONIC.. | 1 0.01 96.67 ARITA N. ANTI VASCULAR ENDOTHELIAL GR.. | 1 0.01 96.68 ARORA A, FLETCHER P. PROBLEM BASED RE.. | 1 0.01 96.69 ASO K ET AL. HYPOTHYROIDISM IN NEONAT.. | 1 0.01 96.70 BARNARDT P, ET AL.. MANAGING AIDS-REL.. | 1 0.01 96.71 BARYLA J., TOKAREWICZ, A.C.. PUPILLAR.. | 1 0.01 96.72 BEATA B, ANITA C, KLARA M, ATTILA K. .. | 1 0.01 96.73 BEN ROMDHANE H, LARIF S, SLIM R, FATH.. | 1 0.01 96.74 BENNA P, MONTALENTI E, CAPRIOLI M. VI.. | 1 0.01 96.75 BERA E.. MATERNAL OUTCOMES FOLLOWING .. | 1 0.01 96.76 BHATTACHARYYA S, YAN K, PENCE L, SIMP.. | 1 0.01 96.77 BOITEN H, HONKOOP P, GREGOOR P. NEPHR.. | 1 0.01 96.78 BORRONI G,TORTI S,PEZZINI C,VASSALLO .. | 1 0.01 96.79 BOURNEAU-MARTIN D, MARTIN-HUYGHE H, M.. | 1 0.01 96.80 BREIVIK H. PAIN MANAGEMENT DISCUSSION.. | 1 0.01 96.81 BROWN J, THANACOODY R. PARACETAMOL-IN.. | 1 0.01 96.82 BS. SUCCESSFUL LONG TERM VAPTAN TREAT.. | 1 0.01 96.83 C. LAROCHELLE, I. METZ, M.A. LECUYER,.. | 1 0.01 96.84 CAIMMI S, AMICI MD, CAIMMI D, LIC.. | 1 0.01 96.85 CAPRIA S, DE ANGELIS F, GENTILE G, TR.. | 1 0.01 96.86 CARRA-DALLIERE, C., MENJOT DE CHAMPFL.. | 1 0.01 96.87 CASTELLINO A, CHIAPPELLA A, GHIONE P,.. | 1 0.01 96.88 CERCHIONE C, MADONNA E, FABBRICINI R,.. | 1 0.01 96.89 CHARI A. A PHASE II STUDY OF PANOBINO.. | 1 0.01 96.90 CHAROENYING Y, CHANSAKULPORN S. PARAC.. | 1 0.01 96.91 CHAVARI-GUERRA Y, SOTO-PEREZ-DE-CELIS.. | 1 0.01 96.92 CHAVEZ P, CASSO DOMINGUEZ A, HERZOG E.. | 1 0.01 96.93 CHIGA M. CONSIDERATION ON 2 CASES OF .. | 1 0.01 96.94 CHOU S, AYABE S, SEKINE N. MYOCARDIAL.. | 1 0.01 96.95 CITTERIO F, PEDROSO JA, PAOLA SALERNO.. | 1 0.01 96.96 CL WONG, NR TUMIAN. PREGNANCY-RELATED.. | 1 0.01 96.97 COLI S, PIGAZZANI F, GAIBAZZI N. MIDV.. | 1 0.01 96.98 CONTRAST-ENHANCING LESIONS WITHIN THE.. | 1 0.01 96.99 CORREIA, I., BATISTA, S., MARQUES, I... | 1 0.01 97.00 CS SIMONSEN, EG CELIUS, SM MOEN. REAL.. | 1 0.01 97.01 CUDZILO CJ, ARAGAKI A, GUITRON J, BEN.. | 1 0.01 97.02 CURTIS RM, SIVILOTTI M. A DESCRIPTIVE.. | 1 0.01 97.03 CUSSANS L, BREHAUT E, PRONOL A, TO T,.. | 1 0.01 97.04 DAISUKE Y, NAITO Y, KINOSHITA S, OSHI.. | 1 0.01 97.05 DARPO B, FERBER G, ZHOU M, SUMERAY M,.. | 1 0.01 97.06 DE MERCANTI, S., ALBERTO ARTUSI, C., .. | 1 0.01 97.07 DEBS, MD R, MAILLART, MD E, FAHED R, .. | 1 0.01 97.08 DESAI CS, KHAN KM, FISHBEIN TM. REUSE.. | 2 0.02 97.10 DICKSON EL, ET AL. TOPOTECAN? FIRST R.. | 1 0.01 97.11 DONOHOE K, LEVINE R. ACQUIRED FACTOR .. | 1 0.01 97.12 DUVAL F,FLABEAU O,RAZAFIMAHEFA J,SPAM.. | 1 0.01 97.13 DUVAL, F., FLABEAU, O., RAZAFIMAHEFA,.. | 1 0.01 97.14 ELIASON, F.. VENLAFAXINE-INDUCED CHRO.. | 1 0.01 97.15 ELMALIK H, ELAZZAZY S, SALEM K AND BU.. | 1 0.01 97.16 EMMI G, SILVESTRI E, CAMELI A, BACHER.. | 1 0.01 97.17 FALLS BA, GURRERA R. SEROTONIN SYNDRO.. | 1 0.01 97.18 FAYETTE J, GUIGAY J, LETOURNEAU C, DE.. | 1 0.01 97.19 FEAGINS LA, FLORES A, ARRIENS C, PARK.. | 1 0.01 97.20 FERRIS VILLANUEVA. REVERSIBLE POSTERI.. | 1 0.01 97.21 FINDLING, R.. ZIPRASIDONE IN ADOLESCE.. | 1 0.01 97.22 FLOHR A, TRUMPER L. OSTEOLYTIC LESION.. | 1 0.01 97.23 FONTAINE H, LAZARUS A, PERIAUX C, BAG.. | 1 0.01 97.24 FOTIADOU C, LAZARIDOU E, SOTIRIOU E, .. | 1 0.01 97.25 GAFFNEY R. SEROTONIN SYNDROME IN A PA.. | 1 0.01 97.26 GAFFNEY RR, SCHREIBMAN IR. SEROTONIN .. | 1 0.01 97.27 GERHARD T, HUYBRECHTS K, SCHNEEWEISS .. | 1 0.01 97.28 GIRAUD V, LONGVERT C, HOULLE-CREPIN S.. | 1 0.01 97.29 GONZVA J, PATRICELLI R,LIGNAC D. SPON.. | 1 0.01 97.30 GRANDVUILLEMIN A,RIPERT C,SGRO C,COLL.. | 1 0.01 97.31 GRAZIA PIRODDI I M, BARLASCINI C, NIC.. | 1 0.01 97.32 GUERN AL, ALKERAYE S, VERMERSCH-LANGL.. | 1 0.01 97.33 GUILLIAMS, K.. HYPOTHERMIA FOR PEDIAT.. | 1 0.01 97.34 GURME M, REED CM, ELIASHIV D. AN INTE.. | 1 0.01 97.35 HADOUX J, REY A, DUVILLARD P, LHOMME .. | 1 0.01 97.36 HAMER, MD H., KNAKE, MD S., SCHOMBURG.. | 1 0.01 97.37 HAMURYUDAN V, SEYAHI E, MELIKOGLU M,.. | 1 0.01 97.38 HAMURYUDAN V, SEYAHI E, MELIKOGLU M, .. | 1 0.01 97.39 HAMURYUDAN V, SEYAHI E, MELIKOGLU M, .. | 1 0.01 97.40 HANAOKA N, MURATA S, HOSOI H, SHIMOKA.. | 1 0.01 97.41 HARALD BREIVIK. EPIDERMAL GROWTH FACT.. | 1 0.01 97.42 HAYASHI H, ET AL.. STEVENS-JOHNSON SY.. | 1 0.01 97.43 HEATH, C.H.. POPULATION-BASED SURVEIL.. | 1 0.01 97.44 HELMERS RA, BYRNE TJ, WESSELIUS LJ, L.. | 1 0.01 97.45 HENN A, DI LUCCA-CHRISMENT J, PICARD-.. | 1 0.01 97.46 HENRICH TJ, HANHAUSER E, MARTY FM, SI.. | 1 0.01 97.47 HERMAN M, RUBIO-TAPIA A, MARIETTA E, .. | 1 0.01 97.48 HEROLD M. BIOREG: SUCCESSFUL BIOLOGIC.. | 2 0.02 97.50 HERRERA, WG ET AL. OCCURRENCE OF A T.. | 1 0.01 97.51 HIGO T, MIYAGAKI T, NAKAMURA F, SHINO.. | 1 0.01 97.52 HIRAI M. AZACITIDINE (AZA) COMBINATIO.. | 1 0.01 97.53 HIROHATA S, HAYASHI S, MUKAI K, MATSU.. | 1 0.01 97.54 HOFFMAN, RS. COULD THERE BE AN ALTERN.. | 1 0.01 97.55 HOLTE H, BERSVENDSEN H, KOLSTAD A, BL.. | 1 0.01 97.56 HONCE JM, NAGAE L, NYBERG E. NEUROIMA.. | 1 0.01 97.57 HORIMOTO Y. . ?:-. | 1 0.01 97.58 HUIS IN ^T VELD D, LUKANDE R, LAMMENS.. | 1 0.01 97.59 HYLAND M, YEANEY G, GOODMAN A. DIAGNO.. | 1 0.01 97.60 IKEDA K. DISCUSSION ON 10 CASES OF DR.. | 1 0.01 97.61 INOUE S, FURUTA J, FUJIMOTO M. A CASE.. | 1 0.01 97.62 IORIO ML, CHEERHARAN M, KAUFMAN SS, R.. | 1 0.01 97.63 ISHIBASHI T, OTA T, FURUKAWA Y, NISHI.. | 1 0.01 97.64 ISHIGURO H. A CASE PRESENTING WITH HY.. | 1 0.01 97.65 ITO Y, OKUMUTA K, KAMIYAMA T, OTOSHI .. | 1 0.01 97.66 ITSUSE K, TSUJI S, UMEDA M, FUKUI S, .. | 1 0.01 97.67 ITSUSE K, TSUJI S, UMEDA M, FUKUI S, .. | 1 0.01 97.68 ITSUSE K, TSUJI SOSUKE, UMEDA MASATAK.. | 1 0.01 97.69 IWAMOTO S, TAKAHASHI T, TAMAGAWA H, N.. | 1 0.01 97.70 IWASAKI H. ONSET OF GRAVES DISEASE DU.. | 1 0.01 97.71 IWATA K,RYOTA N,HIKITA A,SANDO M,SUZU.. | 1 0.01 97.72 JACQUES, F.(1)? BHAN, V.(2). EFFICACY.. | 1 0.01 97.73 JAISWAL SR, CHATTERJEE S, CHAKRABARTI.. | 1 0.01 97.74 JAMES LP, GILL P, SIMPSON P. PREDICTI.. | 1 0.01 97.75 JELCIC I, COMBALUZIER B, JELCIC I, FA.. | 1 0.01 97.76 JONASOVA A. TREATMENT OF MDS 5Q- PATI.. | 1 0.01 97.77 JONES J, PAWLYN C, BRIOLI A, CAIRNS D.. | 1 0.01 97.78 JUNKO DOMATSU ET AL. A CASE REPORT: A.. | 1 0.01 97.79 JUURLINK DN, GOMES T, GUTTMAN A, HEEL.. | 1 0.01 97.80 K IKEDA. DISCUSSION ON 10 CASES OF DR.. | 1 0.01 97.81 K NADARASA, M BAILEY, H CHAHAL, ETAL... | 1 0.01 97.82 KAGAWA R. A REVIEW OF 5 CASES OF SECO.. | 1 0.01 97.83 KAGAWA R. THYROID NEOPLASMS AFTER THE.. | 1 0.01 97.84 KAKOKI K, ARAKI K, IWATA T, MATSUO T,.. | 1 0.01 97.85 KAMEI K, OGURA M, SATO M, SAKO M, IIJ.. | 1 0.01 97.86 KANEKO, K.. A SUCCESSFUL RESPONSE AFT.. | 1 0.01 97.87 KATO M. CURRENT STATUS AND TENDENCY O.. | 1 0.01 97.88 KATO T. DISCUSSION ON 10 CASES OF DRU.. | 1 0.01 97.89 KENDALL B. CASE STUDY:PRADAXA UNDERST.. | 1 0.01 97.90 KENJI UEKI, SHUNSUKE YAMADA, AKIHIRO .. | 1 0.01 97.91 KHANAWAN N, WIROTESANGTHONG M. ANAPHY.. | 1 0.01 97.92 KHARSA ZC, GUSTIN SLF, WESTPHAL LM. P.. | 1 0.01 97.93 KIKUCHI Y. SPECIAL FEATURE KERATOSIS/.. | 1 0.01 97.94 KIM C, LIU R, HSIA D. DIFFUSE ALVEOLA.. | 1 0.01 97.95 KINOSHITA H, FUKUMOTO T, KIDO M, TAKE.. | 1 0.01 97.96 KIRITA Y ET AL.. A CASE OF SUDDEN ONS.. | 1 0.01 97.97 KOBAYASHI H, IEDE KIYOTSUGU, OSHIMA Y.. | 1 0.01 97.98 KOH M-T. UNRECOGNIZED NEAR-FATAL HYPE.. | 1 0.01 97.99 KOMORI K. A CASE OF FULMINANT HEPATI.. | 1 0.01 98.00 KONDO A. A CASE OF SUSPECTED DRUG INT.. | 1 0.01 98.01 KONO H, NAKASUG A, YMAMOTO K, ISHIHAR.. | 1 0.01 98.02 KOSTIK M, DUBKO M, SNEGIRYOVA L, MASA.. | 1 0.01 98.03 KOULOURIS Z, TIERNEY MG, JONES G. MET.. | 1 0.01 98.04 KOVACS A, BAKSAY B, CSERENYECZ A, MOL.. | 1 0.01 98.05 KOZAL MJ.. A PILOT RANDOMIZED, OPEN-L.. | 1 0.01 98.06 KREMENCHUTZKY M, O CONNOR PW. USE OF .. | 2 0.02 98.08 KUBOTA S, ET AL.. PROPHYLACTIC EFFECT.. | 1 0.01 98.09 KUMAGAI R, ICHIMIYA Y.. A MANIC EPIS.. | 1 0.01 98.10 KUZUSHITA N, ET AL.. A CASE OF NONCIR.. | 1 0.01 98.11 LAFAY-CHEBASSIER C, CHAVANT F, FAVREL.. | 1 0.01 98.12 LAM T, CHAN MMK, SWEETING AN, DE SOUS.. | 1 0.01 98.13 LANGE-ASSCHENFELDT C, BLAESER I, SUPP.. | 1 0.01 98.14 LASSEN U, RUIPEREZ A, FLEITAS T, MEUL.. | 1 0.01 98.15 LAU KK, PAPNEJA K. ANTICONVULSANT-IND.. | 1 0.01 98.16 LEGRAND D, BARBATO E, CHENU P, MAGNE .. | 1 0.01 98.17 LEUCOENCEFALOPATIA MULTIFOCAL PROGRES.. | 1 0.01 98.18 LI Y. RHINOSPORIDIOSIS. J DIAGN THER .. | 1 0.01 98.19 LOBATO DE OLIVEIRA E M, FARIA-SIMM R,.. | 1 0.01 98.20 LOHIYA G-S, KRISHNA S, LOHIYA S. ERRO.. | 1 0.01 98.21 LOHIYA, G - S.. ERRORS IN PATIENT HIS.. | 1 0.01 98.22 LUCYK SN, NELSON LS, HOFFMAN RS, HOWL.. | 1 0.01 98.23 LYCKE J. MONOCLONAL ANTIBODY THERAPIE.. | 2 0.02 98.25 LYCKE J. MONOCLONAL ANTIBODY THERAPIE.. | 5 0.05 98.30 M. G. RAINEY. CONSECUTIVE PSEUDOGOUT .. | 1 0.01 98.31 MAKINO S, YADA Y, UMEHARA K, HIGASHI .. | 1 0.01 98.32 MANIX M, WILDEN J, CUELLAR-SAENZ HH. .. | 1 0.01 98.33 MANSO L, VALBUENA T, PADIAL MA, RECHE.. | 1 0.01 98.34 MASACHIKA, E.. SYSTEMIC ERYTHEMA DUE .. | 1 0.01 98.35 MATOS-FERNANDEZ N, RUIZ Y, RODRIGUEZ .. | 1 0.01 98.36 MATSUI O. A CASE OF SINUSOIDAL OBSTRU.. | 1 0.01 98.37 MAUREEN, A. S.. PROGRESSIVE, FATAL TH.. | 1 0.01 98.38 MENDES D, ALVES C, MARQUES FB. SAFETY.. | 1 0.01 98.39 MENDEZ-HERNANDEZ C, SANTOS-BUESO E, M.. | 1 0.01 98.40 MESONJESI E, PLURI E, SINANAI G. AND .. | 1 0.01 98.41 MESQUITA R, SOUSA C, RIBEIRO C, SILVA.. | 1 0.01 98.42 MICHIKO T. A CASE OF PATIENT WITH ADV.. | 1 0.01 98.43 MIKITA N, SHIMA T, DOI N, KAMINAKA C,.. | 1 0.01 98.44 MILLS AT, DAVIDSON ME, YOUNG P. CONCE.. | 1 0.01 98.45 MIYAO, M.. A CASE OF DRUG INDUCED THR.. | 1 0.01 98.46 MIYAZU, D.. THREE CASES WHERE MANAGEM.. | 1 0.01 98.47 MORI T, KOROBOSHI HARUO, MATSUSHIMA H.. | 1 0.01 98.48 MORIWAKA O. USE OF AROMATASE INHIBITO.. | 1 0.01 98.49 MOUCHLI M, FLOMENHOFT D, ANGULO P. EV.. | 1 0.01 98.50 MOWRY JB, SPYKER DA, CANTILENA LR, BA.. | 1 0.01 98.51 MULLER K. A CASE OF SEVERE MYELOTOXIC.. | 1 0.01 98.52 MUNEMOTO Y, MUNEMOTO Y, KANDA M, ISHI.. | 1 0.01 98.53 MUNK K, GORMSEN L, KIM WY, ANDERSEN N.. | 1 0.01 98.54 MYA DH, HAN ST, TAN D, GOH YT. RISK O.. | 1 0.01 98.55 NAGAI K, AOYAGI Y, YAMADA T, TOMIYAMA.. | 1 0.01 98.56 NAITO, N.. ANALYSIS ON THE PATIENTS R.. | 1 0.01 98.57 NAKAMURA K, ASANO Y, SHIBATA S, ET AL.. | 1 0.01 98.58 NAKAMURA M. TUMOR LYSIS SYNDROME DUE .. | 1 0.01 98.59 NAKANISHI, D.. ADVERSE EVENT MONITORI.. | 1 0.01 98.60 NAKASHITA T, ANDO K, KANEKO N, TAKAHA.. | 1 0.01 98.61 NAKAYAMA C. A CASE OF PSORIATIC ONYCH.. | 1 0.01 98.62 NAT AS, NAT A, HARRISON J, RANE M. LI.. | 1 0.01 98.63 NAT AS, NAT A, HARRISON J, RANE M. LI.. | 1 0.01 98.64 NATALIZUMAB ASSOCIATED PML IN A MULTI.. | 1 0.01 98.65 NIISATO, Y.. A CASE OF ENTERITIS PSEU.. | 1 0.01 98.66 NIIYAMA Y ET AL.. A CASE OF CAUDA EQU.. | 1 0.01 98.67 NISHIMURA H. A CASE WITH THE INCREASE.. | 1 0.01 98.68 NOMIYA A ET AL.. A CASE OF DRUG-INDUC.. | 1 0.01 98.69 NUMATA K, ISERO T, OKAMOTO M. A CASE .. | 1 0.01 98.70 OBAYASHI N, SUZUKI M, NAKANO S, MINOW.. | 1 0.01 98.71 OHBO T, FUJISHIRO T, OHARA H, FUJIWAR.. | 1 0.01 98.72 OHTA H, KAWAI H, FUJISHIMA S, ET AL.... | 1 0.01 98.73 OKADA K, ENDO Y, MIYACHI Y, KOIKE Y, .. | 1 0.01 98.74 OKAJIMA R, OKAJIMA A, YAMAGUCHI K, TA.. | 1 0.01 98.75 OKAMOTO S, OGAWA E, YOSHIZAWA A, OKAJ.. | 1 0.01 98.76 OKAZAKI R. A CASE OF LATE-ONSET NEUTR.. | 1 0.01 98.77 ORDONEZ J, KLEINSCHMIDT K, WAX P. NON.. | 1 0.01 98.78 ORLOV S. EFFICACY AND SAFETY OF BCD-0.. | 1 0.01 98.79 OSHIMA K, AKAGI K, TAKADA A, ET. AL.... | 1 0.01 98.80 OYAMA, K.. A CASE OF ACUTE SENSORY NE.. | 1 0.01 98.81 O^CONNOR P, KREMENCHUTZKY M. USE OF N.. | 2 0.02 98.83 O^CONNOR P, KREMENCHUTZKY, M. USE OF .. | 2 0.02 98.85 O^CONNOR P, KREMENCHUTZKY, M. USE OF .. | 4 0.04 98.89 PASQUEL FJ, KLEIN R, ADIGWEME A, HINE.. | 2 0.02 98.91 PASQUEL FJ, KLEIN R, ADIGWEME A, HINE.. | 2 0.02 98.93 PAULZEN M, GRUNDER G, ORLIKOWSKY T, G.. | 1 0.01 98.94 PELLEGRINO P, CARNOVALE C, DANINI T, .. | 1 0.01 98.95 PENAS-PRADO M, HESS K, LEVIN V, DE GR.. | 1 0.01 98.96 PERINI G, PRAVETTONI R, FARINA E, GRA.. | 1 0.01 98.97 PFEFFER G, COTE H, MEZEI M, ET AL. OP.. | 1 0.01 98.98 RAFFEL J, GAFSON A, MALIK O, NICHOLAS.. | 1 0.01 98.99 RANCHON F, CHAUVIN C, SCHWIERTZ V, VA.. | 1 0.01 99.00 REI ATONO. EP-0-13-16 A CASE WITH SEV.. | 1 0.01 99.01 REIKO KAGAWA, ET AL. A REVIEW OF 5 CA.. | 1 0.01 99.02 REISSIG A, KRAINHOFER J, WALTHER M AN.. | 1 0.01 99.03 REPASS TS, WETTER DA, CAMILLERI MJ. T.. | 1 0.01 99.04 REPORTER KNOWN TO HEALTH AUTHORITY. U.. | 1 0.01 99.05 RODRIGUEZ-PINILLA, E.. IMIDAZOLE ANTI.. | 1 0.01 99.06 ROSSI M, CARIOLI G, BONIFAZI M, ZAMBE.. | 1 0.01 99.07 ROXBURGH A, BURNS L, DRUMMER OH, PILG.. | 1 0.01 99.08 RUIZ PENA JL, NAVARRO MASCARELL G, PA.. | 1 0.01 99.09 SADAKI?ASARI. CASE REPORT ACUTE GRAFT.. | 1 0.01 99.10 SAEZ F DN, BLASCO NAVALPOTRO MA, JIME.. | 1 0.01 99.11 SAIJO T,ITO T,IKEDA N. THREE CASES OF.. | 1 0.01 99.12 SAITO M,KASAI Y,OGURA N,MARUYAMA A,GO.. | 1 0.01 99.13 SAKELLAROPOULOU A, THEOFILOS D, BISIR.. | 1 0.01 99.14 SAMALIN E, DE LA FOUCHARDIERE C, THEZ.. | 1 0.01 99.15 SANCHEZ R, PICARD N, MOULY-BANDINI A,.. | 1 0.01 99.16 SATO Y, KUROSAWA H, SAKAMOTO S, KUWAS.. | 1 0.01 99.17 SAVVIDES P, GALANOPOULOS N, LAVERTU P.. | 1 0.01 99.18 SAWADA Y, SATO H, SATO T. A CASE OF P.. | 1 0.01 99.19 SAWAMURA, SOICHIRO. CRIZOTINIB-ASSOCI.. | 1 0.01 99.20 SCHAEFFER T. METHEMOGLOBINEMIA AND HE.. | 1 0.01 99.21 SCHNELL, P. COMPLEX RENAL CYSTS ASSOC.. | 1 0.01 99.22 SEKERES M. ADDITIONAL ANALYSES OF A R.. | 1 0.01 99.23 SENBA, M.. SEVEN CASES OF SUSPECTED D.. | 1 0.01 99.24 SHIBA S, HARADA D, MATSUDA K, MORIGUC.. | 1 0.01 99.25 SHIGEMATSU, S.. A CASE OF OF NONCARDI.. | 1 0.01 99.26 SHINOYAMA M,ISHIHARA H,OKU T,TANAKA N.. | 1 0.01 99.27 SHISHIME, O.. A CASE OF ALK-POSITIVE .. | 1 0.01 99.28 SHPRECHER DR, SLOAN CT, SEDERHOLM B. .. | 1 0.01 99.29 SHUSTER, JOEL. LINEZOLID-ASSOCIATED H.. | 1 0.01 99.30 SILVERMAN G L, NANDHAKUMAR A. ACUTE H.. | 1 0.01 99.31 SINNECKER T, OTHMAN J, KUHL M, MEKLE .. | 1 0.01 99.32 SLAVC I, CHOCHOLOUS M, PEYRL A, GOJO .. | 1 0.01 99.33 SORTING OUT THE RISKS IN PROGRESSIVE .. | 1 0.01 99.34 SRIRATANAVIRIYAKUL N, NGUYEN L-P, HEN.. | 1 0.01 99.35 STARGARD, M., KEGG, S., BRITISH HIV A.. | 1 0.01 99.36 STEGELMANN F, BANGERTER M, GRIESSHAMM.. | 1 0.01 99.37 STEVENSON E, SCHEBRI F, DEBORAH M, JO.. | 1 0.01 99.38 STONE GW, CLAYTON T, DELIARGYRIS EN, .. | 1 0.01 99.39 SUBEI A, ONTANEDA D.RISK MITIGATION S.. | 1 0.01 99.40 SUBEI A, ONTANEDA, D. RISK MITIGATION.. | 1 0.01 99.41 SUBEI AM AND ONTANEDA D. RISK MITIGA.. | 1 0.01 99.42 SUBEI AM, ONTANEDA D. RISK MITIGATION.. | 1 0.01 99.43 SUZUKI Y, MURAKAMI M, SERIKAWA S, SUG.. | 1 0.01 99.44 SWOBODA H, KOPEC K, KOWALSKI MJ, D^OR.. | 1 0.01 99.45 SZAKSZON K. ISTVAN, B. CLINICAL AND B.. | 1 0.01 99.46 TAIRA F, HORIMOTO Y AND SAITO M. TUMO.. | 1 0.01 99.47 TAKAGI Y, HOSOMI Y, OSHITA F, OKAMOTO.. | 1 0.01 99.48 TAKAHASHI T, TAKASAKI T. A CASE OF RH.. | 1 0.01 99.49 TAKUYA I. 48: ONSET OF PNEUMOCYSTIS .. | 1 0.01 99.50 TAMORI A, NORIBUMI K. EFFICACY AND SA.. | 1 0.01 99.51 TANABE Y,MATSUNO K,KOYAMA R,SATO T,TO.. | 1 0.01 99.52 TANAKA M, ISHII H, AZUMA K, SAISHO C,.. | 1 0.01 99.53 TANAKA M. TWO CASES OF EPILEPSY FOLLO.. | 1 0.01 99.54 TANAKA M. TWO CASES OF EPILEPSY FOLLO.. | 1 0.01 99.55 TANAKA, N.. A PATIENT WITH ALK POSITI.. | 1 0.01 99.56 TANAKA, T.. SAFETY OF VARENICLINE FOR.. | 2 0.02 99.58 TETSUYA I, AKIHIKO Y, TOSHIMASA H, ET.. | 1 0.01 99.59 THAKRAR MV, MORLEY K, LORDAN GL, MEAC.. | 1 0.01 99.60 THAKRAR MV, MORLEY K, LORDAN GL, MEAC.. | 1 0.01 99.61 THAKRAR MV, MORLEY K, LORDAN JL, MEAC.. | 1 0.01 99.62 THAKRAR MV, MORLEY K, LORDAN JL, MEAC.. | 1 0.01 99.63 THAKRAR MV, MORLEY K, LORDAN JL, MEAC.. | 1 0.01 99.64 TINTELNOT, K.. A REVIEW OF GERMAN SCE.. | 1 0.01 99.65 TOKUHIRA M, KIMURA Y, NEMOTO T, SAGAW.. | 1 0.01 99.66 UEDA Y. A CASE OF MTX-ASSOCIATED LYMP.. | 1 0.01 99.67 UEKI H, IGARASHI S, KIMURA S, TSUCHIM.. | 1 0.01 99.68 UNKNOWN | 1 0.01 99.69 UNKNOWN. IT MIGHT AS WELL BE COPD, MI.. | 1 0.01 99.70 USUMOTO Y, KUDO K, SAMESHIMA N, SATO .. | 1 0.01 99.71 VALBUENA T, MANSO L, PADIAL MA, RECHE.. | 1 0.01 99.72 VALLET H, SEVE P, RIVIERE S, PERARD L.. | 1 0.01 99.73 VANDAMME M, PAUWELS W, BLEECKER J. A .. | 1 0.01 99.74 VILLA A, ZANADA P, PELLEGRINO A, NUCE.. | 1 0.01 99.75 VILLA A,ZANADA P,PELLEGRINO A,NUCERA .. | 1 0.01 99.76 VITALITI G, MATIN N, TABATABAIE O, DI.. | 1 0.01 99.77 VITALITI G, MATIN N, TABATABAIE O, DI.. | 1 0.01 99.78 VOLONAKI E, MUTALIB M, KIPARISSI F, E.. | 1 0.01 99.79 VOLONAKI E, MUTALIB M, KIPARISSI F, E.. | 1 0.01 99.80 VOLONAKI E, MUTALIB M, KIPARISSI F, E.. | 2 0.02 99.82 WADSWORTH TG, KIESTER J, THOMPSON EG... | 1 0.01 99.83 WANG D, REN A, YE S.. ONE CASE OF FAN.. | 1 0.01 99.84 WATSON,S. DESLORATADINE AND QT PROLON.. | 1 0.01 99.85 WEHLING, M.. PARACETAMOL. EFFICACIOUS.. | 1 0.01 99.86 Y T,K F,S I,A N,S H. INITIAL TREATMEN.. | 1 0.01 99.87 YAMANO T. P 33 A CASE OF CROHN^S DIS.. | 1 0.01 99.88 YAMAZAKI M, SUGIMURA M, KAMIYA F, MIY.. | 1 0.01 99.89 YANG H, WANG K, JIN H, GAO T, XIAO S,.. | 1 0.01 99.90 YASUDA M, IKEGAMI T, IMAI D, WANG H, .. | 1 0.01 99.91 YEE A. RICOLINOSTAT (ACY-1215), THE F.. | 1 0.01 99.92 YILMAZ O.. CHALLENGE-PROVEN NONSTEROI.. | 1 0.01 99.93 YILMAZ, M.. PROSPECTIVE OBSERVATIONAL.. | 1 0.01 99.94 YLIKOTILA P, KETOLA RA, TIMONEN S, MA.. | 2 0.02 99.96 YOSHIDA K, YAMAMOTO K, MORISHIMA A, E.. | 1 0.01 99.97 YOSHIGA D, SASAGURI M, MATSUO K, KOKU.. | 1 0.01 99.98 YOSHINORI U, MITSUHA H, SOTA K, OSAMU.. | 1 0.01 99.99 ZAKI LABIB P, WING S, BHOWMIK A. TRAN.. | 1 0.01 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 6 Apr 2017